Scientific article

Entre sel et gènes ou pharmacogénomique des antihypertenseurs

Published inRevue médicale suisse, vol. 2, no. 61, p. 986-991
Publication date2006

Pharmacogenomics studies the links between polymorphisms (genetic variants) and the variability of the response to some treatments in a given individual. Pharmacogenomics thus allows to explore polymorphisms that could potentially explain heterogeneous efficacy of diuretics, ACE inhibitors or angiotensin receptor blockers, beta-blockers and calcium channel blockers among populations of varied ethnical origin. There have been many studies on the relation between the efficacy of these treatments and the specific polymorphisms involved in the regulation of blood pressure. So far, no unique mutation is by itself predictive of the therapeutic response to these drugs; more elaborated polygenetic models are required so that pharmacogenomics can one day offer an individualized prescription for a complicated disease such as high blood pressure.

  • Antihypertensive Agents/pharmacology/therapeutic use
  • Blood Pressure/drug effects
  • Genomics
  • Humans
  • Hypertension/drug therapy/genetics/metabolism
  • Polymorphism, Genetic
  • Sodium/metabolism
Citation (ISO format)
ERNANDEZ, Thomas et al. Entre sel et gènes ou pharmacogénomique des antihypertenseurs. In: Revue médicale suisse, 2006, vol. 2, n° 61, p. 986–991.
ISSN of the journal1660-9379

Technical informations

Creation11/03/2016 10:33:00 AM
First validation11/03/2016 10:33:00 AM
Update time03/15/2023 1:07:25 AM
Status update03/15/2023 1:07:25 AM
Last indexation01/16/2024 10:39:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack